Innovation at the Core
Pioneering At-Home Precision Injectables
EFX Medical Technologies is developing a new category of self-administered injectables - combining single-use micro-injector cells with anatomically-aligned delivery interfaces to ensure clinical precision, fixed dosing and safety in the home environment.
​
Built from a portfolio of granted and pending patents, the EFX platform eliminates clinician-dependent variability and supports the delivery of botulinum toxin today - and dermal fillers, vaccines, and other biologics tomorrow.
Anthropometric Facial Analysis
Mapping the face with precision.
Our proprietary anthropometric analysis engine applies a high-resolution geometric model to the face, using quantified landmark vectors to determine individualised dimensions and muscle architecture with sub-millimetre accuracy.
The algorithm autonomously assigns the optimal delivery mask, computed against facial topology and the spatial coordinates of targeted muscle bellies including the corrugator, procerus, and frontalis.
This patented, dataset-driven process tailors injection placement across users, eliminating clinician-dependent variability and enabling a consistent, clinically validated foundation for safe, precise, and replicable treatments.
Drug Delivery Mask
Targeted placement, every time.
The patented EFX drug delivery system incorporates pre-calibrated injection points positioned directly over the muscle bellies mapped by our anthropometric analysis system.
The mask ensures exact depth, angle, and spacing for each injection - providing clinically verified accuracy and reproducible outcomes.
Designed for both aesthetic and therapeutic use, it bridges human anatomy with mechanical precision.
Dual Chamber Micro-Injector Cell Solutions
Miniaturised, self-contained injectors for lyophilised biologics.
Our flagship injector cell is a dual-chamber, single-use system that safely stores, reconstitutes, and delivers lyophilised botulinum toxin at micro-volume precision.
​
Activation opens an internal fluid path, combining diluent and powder instantly within a sterile microchamber before injection.
The closed, disposable design eliminates contamination risk, ensures dosage accuracy, and simplifies handling for patients and clinicians alike.
In-Solution Injector Cell Systems
Optimised for stability and single-dose delivery.
Building on the core EFX platform, our filler delivery system integrates anthropometric facial analysis, anatomically aligned positioning masks, and precision-controlled injector cells to ensure accurate placement of highly viscous materials.
The system is being engineered to compute and deliver consistent volume, depth, and spatial distribution across defined contouring sites, reducing clinician-dependent variation and bias to enhance predictability of aesthetic outcomes.
By extending the full EFX technology stack to dermal fillers, this next-generation solution supports greater safety, symmetry, and reproducibility in both clinical and future at-home treatment environments.
Cosmetic Filler Solutions
Controlled volume, consistent depth.
Building on the EFX dual-chamber foundation, our filler injector cell is being developed to deliver viscous materials with consistent volume and depth control.
​
This next-generation delivery platform aims to reduce manual variability in dermal filler placement, supporting superior contouring and safety outcomes in clinical and at-home settings.
Needless Dual-Chamber System
For volatile and oxidation-sensitive materials.
EFX is exploring a needleless variation of its dual-chamber injector architecture designed for compounds such as L-Ascorbic Acid and other volatile or oxygen-sensitive formulations.
​
The system enables hermetically sealed reconstitution - advancing non-invasive self-administration for future therapeutic and cosmetic applications.
Every stage of our R&D pipeline is guided by a single principle: to transform injectable medicine into an accessible, precision-guided, and patient-first experience.
Through continued collaboration with pharmaceutical partners, regulatory bodies, and manufacturing specialists, EFX Medical Technologies is pursuing a commercialisation strategy based on licensing, co-development, and supply partnerships with pharmaceutical manufacturers across aesthetic and therapeutic drug classes.
Beyond Aesthetics
Broader Medical Applications
The EFX injector cell platform is adaptable to a range of therapeutic applications requiring rapid, precise, single-dose delivery - including vaccines, peptides, and protein-based biologics.
Applications under evaluation include rapid-response influenza and mRNA vaccine delivery, as well as other dose-critical biologic therapies.